---
title: "ADAR1 Capital Management reports acquisition of $34,571.592 in Mentari Therapeutics common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304932745.md"
description: "ADAR1 Capital Management, managed by Daniel Schneeberger, acquired 2,640 common shares of Mentari Therapeutics at $13.0953 per share, totaling $34,571.592. Following this purchase, indirect beneficial ownership reached 98,297 shares. Schneeberger is listed as a 10% owner of the company."
datetime: "2026-11-10T01:19:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304932745.md)
  - [en](https://longbridge.com/en/news/304932745.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304932745.md)
generator: "portal-rs"
---

# ADAR1 Capital Management reports acquisition of $34,571.592 in Mentari Therapeutics common shares

-   ADAR1 Capital Management reported purchasing 2,640 Mentari Therapeutics common shares at $13.0953 per share. \* Indirect beneficial ownership totaled 98,297 common shares following the purchase. \* Joint reporting owner Daniel Schneeberger, manager of ADAR1 Capital Management, was listed as a 10% owner. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001940272-26-000031), on November 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed Pharmaceuticals](https://longbridge.com/en/news/305072970.md)
- [Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30](https://longbridge.com/en/news/305028486.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**